Are we proof that a new drug to stop diseases like arthritis

Mahn Singh is the first British child to be part of a trial for a new drug, teplizumab, which blocks the immune system malfunction that destroys insulin-producing cells and causes type 1 diabetes.

Related Keywords

Northwick , Cheshire West And Chester , United Kingdom , North Yorkshire , London , City Of , Harrogate , Dealing , Britain , Britons , British , Rachel Besser , Paul Howard , Wendy Holden , Kevan Herold , Harj Mahn , Mikayla Olsen , Hilary Nathan , Colin Dayan , Mahn Singh , Daisy Abbs , Joe Brunwin , Drug Administration , Yale School Of Medicine , Department Of Health , National Screening Committee , National Diabetes Audit , Oxford University , Good Health , Innovation Advisory Committee , Cardiff University , University Hospital Of Wales , Regulatory Agency , Diabetes Research Foundation , Ms Society , Newborn Research , West London , Recent Onset Type , Trial Evaluating Efficacy , Northwick Park Hospital , University Hospital , Sheffield Children , Professor Colin Dayan , New England Journal , Yale School , Juvenile Diabetes Research Foundation , Diabetes Audit , National Screening , Innovation Passport , Social Care , Arthritis United , Lupus United Kingdom , Dailymail , Health , Diabetes ,